Achaogen Inc (NASDAQ:AKAO) Given Consensus Recommendation of “Hold” by Analysts

Achaogen Inc (NASDAQ:AKAO) has been assigned an average rating of “Hold” from the twelve ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation and ten have issued a hold recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $2.71.

Several equities analysts have weighed in on the company. Zacks Investment Research cut Achaogen from a “buy” rating to a “hold” rating in a research note on Thursday, April 11th. Needham & Company LLC restated a “hold” rating on shares of Achaogen in a research note on Friday, March 29th. Finally, HC Wainwright restated a “hold” rating and set a $2.00 price objective on shares of Achaogen in a research note on Thursday, February 21st.

Shares of NASDAQ:AKAO opened at $0.11 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.77 and a debt-to-equity ratio of 1.00. Achaogen has a 1-year low of $0.10 and a 1-year high of $15.00. The firm has a market cap of $7.03 million, a price-to-earnings ratio of -0.03 and a beta of 0.78.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of Achaogen by 42.9% during the 4th quarter. Rhumbline Advisers now owns 41,268 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 12,383 shares during the period. Bank of Nova Scotia raised its stake in shares of Achaogen by 900.0% during the 4th quarter. Bank of Nova Scotia now owns 50,000 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 45,000 shares during the period. Virtu Financial LLC bought a new stake in shares of Achaogen during the 1st quarter worth $26,000. JPMorgan Chase & Co. raised its stake in shares of Achaogen by 2,745.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 294,768 shares of the biopharmaceutical company’s stock worth $1,176,000 after purchasing an additional 284,407 shares during the period. Finally, Deutsche Bank AG raised its stake in shares of Achaogen by 94.5% during the 4th quarter. Deutsche Bank AG now owns 392,478 shares of the biopharmaceutical company’s stock worth $482,000 after purchasing an additional 190,715 shares during the period. Institutional investors own 31.85% of the company’s stock.

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Featured Article: Investing strategies using the yield curve

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.